Lucid Diagnostics/$LUCD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Ticker
$LUCD
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
72
ISIN
US54948X1090
Website
LUCD Metrics
BasicAdvanced
$141M
-
-$1.26
1.32
-
Price and volume
Market cap
$141M
Beta
1.32
52-week high
$1.80
52-week low
$0.68
Average daily volume
1.1M
Financial strength
Current ratio
0.753
Quick ratio
0.714
Long term debt to equity
-29.812
Total debt to equity
-655.942
Interest coverage (TTM)
-2,075.96%
Management effectiveness
Return on assets (TTM)
-92.04%
Return on equity (TTM)
-1,897.35%
Valuation
Price to revenue (TTM)
17.589
Price to book
-1.83
Price to tangible book (TTM)
-1.82
Price to free cash flow (TTM)
-1.642
Growth
Revenue change (TTM)
39.89%
Earnings per share change (TTM)
-1.46%
3-year revenue growth (CAGR)
82.28%
3-year earnings per share growth (CAGR)
-6.52%
What the Analysts think about LUCD
Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.
LUCD Financial Performance
Revenues and expenses
LUCD Earnings Performance
Company profitability
LUCD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lucid Diagnostics stock?
Lucid Diagnostics (LUCD) has a market cap of $141M as of June 11, 2025.
What is the P/E ratio for Lucid Diagnostics stock?
The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of June 11, 2025.
Does Lucid Diagnostics stock pay dividends?
No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of June 11, 2025.
When is the next Lucid Diagnostics dividend payment date?
Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.
What is the beta indicator for Lucid Diagnostics?
Lucid Diagnostics (LUCD) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.